While there, for chemotherapy, exists neither epidemiological evidence nor any biological mechanism to suggest that the effect would be different for ER-positive and ER-negative cancers, this is not the case for endocrine therapy, which we therefore investigated further. Here, ESR1 is linked to cancer.